awmsg logo



levofloxacin (Quinsair®)


Reference No. 1012

Publication date:
21/11/2016


Appraisal information

levofloxacin (Quinsair®) 240 mg nebuliser solution


Company: Horizon Pharma plc
BNF category: Infections
NMG meeting date: 05/10/2016
AWMSG meeting date: 09/11/2016
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 3016
Ministerial ratification: 18/11/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Levofloxacin (Quinsair®) is recommended as an option for restricted use within NHS Wales. Levofloxacin (Quinsair®) should be restricted for use as a third-line therapy in patients who do not respond to, or are intolerant of, second-line treatment with tobramycin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Levofloxacin (Quinsair®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download